AbbVie Inc. (ABBV) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 28 wire items for ABBV, including 21 press releases and news items, 5 SEC filings and 1 insider trade. The most recent was published Nov 3, 2026.
ABBV rankings
Price$285.89+40.80 (+16.65%)
2026-08-032026-11-03
Financial highlights
Full financials- Revenue, TTM
- $66.01B
- Revenue growth
- +10.7%
- Net income, TTM
- $10.34B
- Net margin
- 15.7%
- Free cash flow, TTM
- $18.87B
- Cash
- $10.77B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks132+24%
2026-05-102026-11-01
Mix6690d
- Other50(76%)
- SEC Filings8(12%)
- Insider4(6%)
- Earnings2(3%)
- Analyst1(2%)
- Dividends1(2%)
Latest news
25 items- SECSEC Form 10-Q filed by AbbVie Inc.10-Q - AbbVie Inc. (0001551152) (Filer)
- PRAllergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes– A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX® Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session– Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" reportIRVINE, Calif., Nov.
- SECAbbVie Inc. filed SEC Form 8-K: Leadership Update8-K - AbbVie Inc. (0001551152) (Filer)
- PRBrise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine TherapiesBEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE:ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise's preclinical migraine programs. "This collaboration represents an important validation of our research platform in migraine and advances our mission to deliver potentially transformative medicines to patients," said Guochun Li, Chief Executive Officer of Brise Pharmaceuticals. "By partnering with a global leader like
- SECAbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Reports Third-Quarter 2026 Financial ResultsReports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $17.404 Billion, an Increase of 10.3 Percent on a Reported Basis or 10.5 Percent on an Operational BasisThird-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis, or 16.6 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $5.776 Billion; Global Rinvoq Net Revenues Were $2.706 Billion; Global Humi
- PRAbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention TrialPhase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more migraine days per month.1Atogepant (QULIPTA®) demonstrated superior efficacy across key clinical and functional outcomes, including reductions in monthly migraine days and improvements in headache-related disability, daily functioning and cognitive function.125% of Canadian households are impacted by migraine.2MONTREAL, Oct. 29, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head s
- PRThe Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1BOTOX® Cosmetic Day marks the biggest offer of the year for Allē Members.IRVINE, Calif., Oct. 28, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the return of BOTOX® Cosmetic Day on Wednesday, Nov. 18, 2026. Now in its eighth year, BOTOX® Cosmetic Day invites new and existing patients to book a comprehensive consultation with a licensed aesthetic specialist to discuss their personalized treatment options. In addition to a BOGO (buy-one-get-one) free $50 gift card offer*, the brand's
- PRAllergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence.In 2026 alone, BOTOX® Cosmetic awarded 20 women entrepreneurs each with a $20,000 grant to help advance their business goals.IRVINE, Calif., Oct. 27, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 20 grant recipients who each received $20,000 from BOTOX® Cosmetic through The Confidence Collective: Empowering Women Entrepreneurs. This ongoing initiative is dedicated to closing the confidence gap and accelerating business growth for women founders.
- PRAbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in community-based care– In the Phase 3 CERVINO study, etentamig achieved statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) versus investigator's choice of standard available therapies– Submission underscores AbbVie's ambition to advance a broad multiple myeloma portfolio that addresses disease complexity and supports patients' evolving care goals NORTH CHICAGO, Ill., Oct. 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today anno
- PRAllergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide.A STEM-focused workshop in San Antonio will bring together 20 Girls Inc. participants and alumnae for an educational experience and private panel discussion with local women healthcare providers.For the third consecutive year, SkinSpirit, the nation's premier destination for medical aesthetics, invites clients to support the next generation of women leaders through its SkinSpirit Gives initiative.IRVINE, Calif., Oct. 26, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, is celebrating eight years of partnership with Girls Inc., a
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-19) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 10/23/2026. Application Category: BLA, Application Number: 761262, Application Classification:
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-53) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 10/23/2026. Application Category: BLA, Application Number: 761105, Application Classification:
- INSIDERSEC Form 3 filed by AbbVie Inc.3 - AbbVie Inc. (0001551152) (Issuer)
- PRU.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseNow with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatmentIn the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiiiThe safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identifiedFDA also approved an update to the U.S. Prescribing Information
- PRAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaIn the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physiciansLutikizumab was generally well tolerated, with no new safety concerns identified1INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to se
- PRAllergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ EvidenceAllergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® CosmeticThe latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight lossThe company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supp
- PRAbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian CancerOvarian cancer is the leading cause of death from gynecological cancers in Canada. 1ELAHERE® (mirvetuximab soravtansine) offers a targeted treatment option for Canadians living with FRα-positive, platinum-resistant ovarian cancer, where significant needs remain.2,3The agreement marks an important milestone toward public reimbursement of ELAHERE® in Canada, with provincial and territorial listing decisions to follow.MONTREAL, Oct. 21, 2026 /CNW/ -- AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a Letter of Intent (LOI) has been signed by both
- PRHealth Canada Approves SKYRIZI® (risankizumab) for Children Living with Moderate to Severe Plaque PsoriasisPsoriasis affects 1 million Canadians, and nearly one-third of people living with psoriasis develop symptoms before age 18, meaning the disease can begin during important formative years.1Pediatric psoriasis can have a significant impact on children and their families. A recent systematic review found 84.8% of children with psoriasis and 96.1% of caregivers experienced some degree of health-related quality-of-life impairment.2Health Canada's approval expands treatment to pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.3MONTREAL, Oct. 20, 2026 /CNW/ -- AbbVie (NYSE:ABBV), announced today that Health
- PRAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseaseIn a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 241Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 241The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week CongressNORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today anno
- PR/C O R R E C T I O N - AbbVie/In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combi
- PRAbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioNew and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicineAbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of developmentPresentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere®(mirvetuximab soravtansine-gynx)NORTH CHICAGO, Ill., Oct. 1
- PRSKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 202620 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitisNew data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presentedNORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the presentation of 20 new scientific abstracts from its IBD
- SECSEC Form 8-K filed by AbbVie Inc.8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's DiseaseHigher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 findings in which SKYRIZI achieved superiority in the co-primary endpoints of clinical remission and endoscopic response versus placeboThese data support the application to the U.S. Food and Drug Administration seeking approval of a subcutaneous induction dosing regimen for SKYRIZI for patients with moderately to severely active Crohn's diseaseNORTH CHICAGO, Ill., Oct. 13, 2026 /PRNewswire/ -- AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction tr
ABBV FAQ
12 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...What is the latest news on ABBV?
In the last 30 days Quantisnow tracked 28 wire items for ABBV: 21 press releases and news items, 5 SEC filings, 1 insider trade and 1 earnings update. The most recent was published on November 3, 2026.What is ABBV revenue?
AbbVie Inc. (ABBV) reported $66.01B of revenue for the twelve months ended Sep 30, 2026. That is up 10.7% from the year before. Revenue for fiscal 2025 was $61.16B.Is ABBV profitable?
Yes. AbbVie Inc. earned $10.34B in net income for the twelve months ended Sep 30, 2026, a net margin of 15.7%.How much cash and debt does ABBV have?
AbbVie Inc. reported $10.77B in cash and cash equivalents and $72.23B of debt on its most recent balance sheet in SEC filings.Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.Does ABBV pay a dividend?
Yes. ABBV's next ex-dividend date is 2027-01-15 with a declared cash dividend of $1.82 per share, payable 2027-02-16.What are analysts saying about ABBV?
Across the last 8 analyst actions on AbbVie Inc., there were 3 upgrades and 1 downgrade. The most recent action was from Wolfe Research: Outperform with a $300.00 price target on 2026-08-13. Recent price targets range from $234.00 to $300.00.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.